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Abstract
Purpose This phase II trial first describes the combination
chemotherapy of biweekly irinotecan plus S-1 (biweekly
IRIS) for pretreated advanced gastric cancer (AGC) patients.
Methods Patients who had previously been treated with
greater than or equal to one regimen were enrolled. They
received S-1 35 mg/m2 twice daily on days 1–14 and iri-
notecan 150 mg/m2 on days 1 and 15, every 4 weeks. The
primary endpoint was overall survival (OS).
Results Among the 38 patients enrolled, 18 patients were
treated as second line, and the remaining 20 patients were
enrolled as third- or fourth line. A total of 208 cycles
were administered with the median being four cycles
(range 1–16). The median OS was 8.7 months [95% con-
fidence interval (CI) 7.5–10.3], and the median progres-
sion-free survival was 6.3 months (95% CI 5.3–7.3). Low
serum albumin (\3.5 mg/dL) was an independent adverse
prognosticator for survival. Overall response rate was 17%
(95% CI 4–30%). The major grade 3/4 toxicities were
neutropenia (26%) and diarrhea (18%).
Conclusions Biweekly IRIS showed the moderate activ-
ity as salvage treatment in AGC. Considering high
neutropenia and gastrointestinal toxicity, patient selection
should be warranted; serum albumin may be a predictive
factor for treatment decision.
Keywords Gastric cancer  Chemotherapy 
Clinical trial  S-1  Irinotecan
Introduction
Although gastric cancer is considered chemosensitive, the
prognosis is still poor and prolonging survival and
improving the quality of life are challenges for oncologists.
Combining chemotherapies is the standard approach in
metastatic or recurrent gastric cancer, but the overall
response rate (ORR) of first-line chemotherapy has been
only 35–45%, with a median progression-free survival
(PFS) of 5–6 months [1]. This means that many patients
eventually develop progressive disease (PD) leading to
treatment cessation. Recent advances of chemotherapy
have enabled many patients to maintain good performance
status even after first-line chemotherapy. In Asian
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countries, including Korea, salvage chemotherapy is
widely accepted after first-line treatment fails assuming
that it might be helpful for survival prolongation, but little
is known about the indication, outcomes, and predictive
factors for salvage chemotherapy [2]. Recently, some tri-
als—mainly phase II studies—have been conducted for this
clinical setting. Various chemotherapy regimens have been
tried; cisplatin combinations have shown ORR of 19–45%
[3–5]; paclitaxel combinations have shown ORR of
22–27% [6, 7]; and irinotecan-based regimens have shown
ORR of 12–31% [8–10]. However, tumor responses and
their durations were heterogenous, depending on treatment
regimens, response and composition of previous chemo-
therapy, and patient selected. Moreover, considerable tox-
icity accompanied many of these regimens. Therefore,
prolonging survival with maintaining general performance
should be a goal of salvage chemotherapy.
S-1 is one of the active agents currently available in
gastric cancer. Encouraging results from several studies
evaluating the efficacy of combination partners with S-1
have been reported. Among these, irinotecan is the only
agent proving that second-line chemotherapy prolongs
survival when compared with best supportive care [11].
Although the study is insufficient—too small patients (only
40 patients) were randomized due to poor accrual to pro-
vide convincing evidence of benefit of salvage chemo-
therapy—irinotecan could be a reasonable partner for
combination with S-1, preclinically and clinically. Irino-
tecan combined with 5-fluorouracil (5-FU) has proven
efficacy in colorectal cancer and is also supposed to be
active against gastric cancer. Recently, a systematic review
suggested irinotecan/5-FU be an appropriate alternative
to 5-FU/cisplatin, with a moderate survival benefit and
more favorable toxicity profiles [12]. In vitro synergism,
different action and toxicity mechanisms, and a lack of
cross-resistance also justify combining these two agents.
A preclinical study showed that combining SN-38 followed
by 5-FU inhibited thymidylate synthase (TS) for a longer
period and increased 5-FU metabolite integration into
DNA [13]. Moreover, irinotecan reduces TS gene expres-
sion, and combining these agents has potent antitumor
activity in 5-FU resistant cells [14]. Based on these find-
ings, we conducted the first clinical study to investigate the
feasibility of these combinations as salvage treatment after
failure of previous chemotherapy.
Patients and methods
Eligibility
Patients with histologically confirmed recurrent or meta-
static gastric adenocarcinoma were considered eligible
when they met all the following criteria: (1) age C 18
years; (2) Eastern Cooperative Oncology Group (ECOG)
performance scale B 2; (3) evaluable disease with or
without measurable lesions; (4) disease progression after
previous chemotherapies within 3 months before entry,
with a maximum of three previous regimens, including
neoadjuvant or adjuvant chemotherapy; and (5) adequate
hematological, renal, and hepatic functions. The latter was
defined as neutrophil C 1,500/mm3, platelet C 100,000/
mm3, serum creatinine B 1.5 mg/dL, total bilirubin B 1.25
(or 1.5) 9 upper limit of normal (ULN), and serum
transaminases B 2.5 (or 5.0) 9 ULN in the absence
(or presence) of liver metastasis. Patients were excluded if
they had concurrent malignancy within the past 5 years
(excluding basal cell carcinoma of the skin or cervical
carcinoma in situ), symptomatic metastasis to brain, or
uncontrolled significant comorbidity. The protocol was
approved by the Institutional Review Board, and all the
patients gave informed consent before enrollment.
Treatment and dose adjustments
Irinotecan was administered biweekly on days 1 and 15.
The starting dose was 150 mg/m2 infused intravenously for
2 h. The S-1 dose was 35 mg/m2 twice daily, which was
administered for 14 consecutive days (days 1–14) followed
by a 14-day resting period. S-1 dosage was calculated
based on the body surface area, which differs from
the Japanese guide [15]. The cycle was repeated every
4 weeks. Patients were premedicated with routine
antiemetics.
If grade 2 neutropenia occurred on the day 15, irinotecan
dose was reduced to 120 mg/m2. If grade C 3 neutropenia
developed, irinotecan was skipped. For patients developing
grade 4 neutropenia (or any grade febrile neutropenia),
grade 4 thrombocytopenia, grade C 3 or recurrent grade 2
diarrhea or mucositis, grade C 3 lethargy, or grade C 2
hyperbilirubinemia, treatment was stopped until resolution
and restarted with reduced dose of S-1 (30 mg/m2 followed
by 25 mg/m2) and irinotecan (120 mg/m2 followed by
100 mg/m2). The resolution of hematological toxicity
was defined as neutrophil C 1,500/mm3 and platelets C
75,000/mm3, respectively. In the event of severe toxicities,
despite dose modifications, irinotecan was further reduced
to 75 mg/m2.
Granulocyte colony-stimulating factor (G-CSF) was
therapeutically indicated when patients developed grade 4
neutropenia, but prophylactic use of G-CSF was also
allowed to prevent more severe neutropenia. Patients who
required[6-week delay to recover from any toxicity other
than alopecia and anemia or who required dose reduction
due to toxicity above the planned modification step were
withdrawn from the study. Chemotherapy was continued
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until there was disease progression, unacceptable toxicity,
or the patient’s withdrawal.
Response and toxicity assessment
Baseline evaluations included a complete medical history
with physical examination, performance status, complete
blood count (CBC), serum chemistries, tumor markers
[carcinoembryonic antigen (CEA), CA19-9], urinalysis,
and electrocardiography. A radiological examination of
each lesion was carried out within 3 weeks before the
treatment. Fiberoptic gastroduodenoscopy was planned to
evaluate complete responders. Physical examination, CBC,
and serum chemistries were planned at days 1 and 15 of the
cycle. For tumor response evaluation, imaging studies were
repeated every two cycles.
Treatment response was evaluated using spiral com-
puted tomography according to the guidelines of the
Response Evaluation Criteria in Solid Tumors Committee
(RECIST, version 1.0) by independent radiologists. The
response was assessed according to intention-to-treat (ITT)
analysis. Patients were considered assessable for response
when they had received a minimum of two cycles with at
least one tumor measurement, or when they had clinical or
radiologic evidence of early disease progression within first
two cycles. Toxicities were evaluated and recorded as a
grade according to the NCI—Common Toxicity Criteria
(version 3.0).
Statistical analysis
The primary endpoint of the study was overall survival
(OS), and the secondary endpoints were PFS, ORR, dis-
ease-control rate (DCR), and toxicity. OS was defined from
the treatment start to death of any cause. PFS was defined
from the treatment start to disease progression or death of
any cause. We tested the hypothesis that mean survival
time (MST) would improve by 75% compared with his-
torical controls. The study was designed to have a 90%
power to show an improvement in OS from 3.8 to
6.6 months with a 10% type I error, using one-sided testing
and assuming exponential OS times. Planned patient
accrual time was 18 months, and follow-up period was
6 months. A sample size of 34 patients was required [16].
Considering a 10% dropout rate, 38 patients were needed
for this trial. Association between clinicopathological
parameters was analyzed with Fisher’s exact test. Time-
dependent variables were analyzed using the Kaplan–Meier
method and compared using the log-rank test. Multivariate
analysis was carried out using Cox’s proportional hazards
regression model. Exact 95% confidence interval (CI) was
provided for proportions.
Results
Patient characteristics
From May 2007 to December 2008, a total of 38 patients
were enrolled. Patient characteristics are summarized in
Table 1. The median age was 57 years. Eighteen patients
(47%) received study agents as second-line treatment and
remaining 20 patients (53%) as third- or fourth-line treat-
ment. Twenty-two patients (58%) had prior gastrectomy;
among whom, 17 (45%) got curative-aim resection.
Table 1 Patient characteristics
Baseline clinicopathologic
features
Patient
number
Total enrolled 38
Response evaluable patients 35
Age, median (range) 57 (34–77)
Sex (%)
Male 21 (55)
Female 17 (45)
Performance status (ECOG)
0 7 (18)
1 28 (74)
2 3 (8)
Previous chemotherapy (%)
First line 18 (47)
Second line 13 (34)
Third line 7 (18)
Histology (%)
Well and moderately differentiated 12 (32)
Poorly differentiated 16 (42)
Signet ring cell 9 (24)
Others 1 (3)
Previous gastrectomy (%)
None 16 (42)
Curative 17 (45)
Palliative 5 (13)
Number of metastasis site
1 11 (29)
2 14 (37)
C3 13 (34)
Disease site (%)
Abdominal lymph node 24 (31)
Peritoneum 19 (25)
Liver 9 (12)
Cervical lymph node 6 (8)
Lung 3 (4)
Others 16 (21)
ECOG Eastern Cooperative Oncology Group
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Abdominal lymph nodes were the main site of metastasis.
Peritoneal seeding was noted in 19 (25%) patients.
Previous chemotherapy histories of the patients are
summarized in Table 2. There was a median of 23 (range
10–91) days from documenting disease progression of
previous treatment to study treatment. Fourteen patients
had progressive disease during chemotherapy-off period.
Median 7.5 cycles (range 2–14) of first-line chemotherapy
were administered, with a median relative dose intensity
(RDI) of 0.97 (range 0.76–1.0). The ORR of first-line
chemotherapy was 37%. Twenty patients received second-
line chemotherapy with a median cycle, and RDI were four
(range 2–14) and 0.95 (range 0.64–1.0), respectively. The
ORR of second-line chemotherapy was 20%. Finally, seven
patients received third-line chemotherapy for the median
four cycles (range 2–6), with the median RDI of 0.86
(range 0.63–1.0) and 14% ORRs. This implies that the
patients enrolled received enough doses and cycles of
previous chemotherapy.
Treatment summary
A total of 208 cycles were administered, with a median of
four cycles (range 1–16) per patient. The median dose
intensity of irinotecan and S-1 was 61 mg/m2/week (range
27.8–71.0) and 210 mg/m2/week (range 91–245 mg/m2/
week), respectively, which corresponds to RDIs of 0.81
and 0.86, respectively. All but nine patients had to delay
next cycles with the median delay of 3 weeks (range 2–6).
Ten patients were subjected to dose reduction due to tox-
icity; hematologic toxicity (n = 5), diarrhea (n = 3), and
mucositis (n = 2), respectively. After PD on this regimen,
ten patients (55%) who received study treatment as second
line were transferred to further chemotherapy: taxane
monotherapy (n = 5) and oxaliplatin combination (n = 5).
Nine patients (44%) as third- or fourth-line treatment were
transferred to further chemotherapy: taxanes monotherapy
(n = 4), oxaliplatin combination (n = 3), and other oral
fluorouracils (n = 2).
Efficacy
With the median follow-up duration of 8.2 months (range
3.4–23.1), 33 patients had PD and 30 (79%) died from
cancer. The MST was 8.7 months (95% CI 7.5–10.3)
(Fig. 1a); 11.6 months (95% CI 4.8–18.4) for the second-
line treatment group and 7.6 months (95% CI 3.9–8.8) for
the third-line or more treatment groups. The one-year
survival rate of all patients was 36% (42% for the second-
line group, 20% for the third-line group, and 14% for the
fourth-line group).
The median PFS was 6.3 months (95% CI 5.3–7.3)
(Fig. 1b); 6.5 months (95% CI 5.3–7.7) for the second-line
group, and 5.6 months (95% CI 3.9–7.3) for the third-line
or more treatment groups. On multivariate analysis for
survival, low serum albumin (\3.5 mg/dL) (OR = 6.43,
P \ 0.001) was the most significant independent adverse
prognosticators for OS (Table 3). Old age (C65) and prior
exposure to capecitabine comprised other independent
factors for poor survival. For PFS, liver metastasis
(OR = 5.74) and low serum albumin (OR = 2.89) were
the adverse factors.
Tumor response was assessable in all but three patients
who had non-measurable lesions only. Objective responses
were observed in 6 patients, and 19 had stable disease
(SD). The ORR was 17% (95% CI 4–30%). Among the
objective responders, four received the study agents as
second-line treatment and the other two patients as third-
line treatment. Their median response duration was
4.5 months (range 2.0–12.0).
Table 2 Summary of prior
chemotherapy regimens
NA not assessable, RDI relative
dose intensity, 5-FU
5-fluorouracil
a Pemetrexed ? cisplatin;
capecitabine ? doccetaxel
b 5-FU ? adriamycin (n = 2),
5-FU ? cisplatin,
capecitabine ? cisplatin,
vinflunine
Treatment group Number of enrolled
patients
Median cycles
(range)
Median RDI
(range)
First line 38 7.5 (2–14) 0.97 (0.76–1)
(Oral) 5-FU ? cisplatin 12 6 (3–12) 1.0 (0.76–1)
Taxanes ? 5-FU 9 8 (2–12) 1.0 (0.81–1)
Taxanes ? cisplatin 9 8 (3–11) 0.96 (0.89–1)
(Oral) 5-FU ? oxaliplatin 6 8.5 (6–14) 1.0 (0.89–1)
Othersa 2 NA NA
Second line 20 4 (2–14) 0.95 (0.64–1)
Taxanes ? 5-FU 10 2 (1–9) 0.93 (0.64–1)
(Oral) 5-FU ? oxaliplatin 5 9 (2–14) 0.95 (0.76–1)
Othersb 5 NA NA
Third line 7 4 (2–6) 0.86 (0.63–1)
(Oral) 5-FU ? oxaliplatin 4 3.5 (2–6) 0.82 (0.63–1)
Taxanes 3 4 (4–6) 0.86 (0.73–1)
994 Cancer Chemother Pharmacol (2011) 68:991–999
123
The DCR was 71% (95% CI 56–86%). The median
duration of disease control was 7.3 months (range 2.0–22.4).
We evaluated DCR separately by previous treatment. For
the second-line treatment group, the DCR was 83% and the
median duration was 8.1 months (range 3.3–19.3). For the
third-line or more treatment groups, the DCR was 60%,
with the median duration of 5.7 months (range 3.5–22.4).
Toxicity
The toxicity profile is summarized in Table 4. There was
no treatment-related mortality. The most common grade
3/4 hematologic toxicity was neutropenia, which was found
in 26% of the patients, and three patients (8%) suffered
febrile neutropenia. Grade 3/4 leukopenia and anemia were
also observed in 27 and 19% of the patients, respectively.
Twenty-three patients required G-CSF support, but none of
them suffered febrile neutropenia. The median frequency
of G-CSF administration was 2 (range 1–10). The most
common grade 3/4 non-hematological toxic effects were
diarrhea (18%), mucositis (8%), and hyperbilirubinemia
(6%).
Discussion
Whether the benefit of chemotherapy will continue with
disease progression during or after first-line treatment is still
unclear [11]. There are few randomized trials investigating
the efficacy and safety of salvage chemotherapy, and most
phase II trials are from Japan, Korea, and Italy, where the
practice of offering second-line chemotherapy is common
[1]. But it is consistent findings from pooled analysis that
responders to second-line chemotherapy survive longer
compared with non-responders, and symptomatic benefit
may be obtained from the second-line therapy [17]. Old
agents have been rapidly replaced by newer drugs including
taxanes, irinotecan, and oxaliplatin, which prove to be more
effective and better tolerated in gastric cancer. Therefore, we
designed this study of combined S-1 and irinotecan assuming
that newer drugs are a rational option for salvage treatment as
it is for first-line treatments.
The first point to consider is the treatment schedule.
Many schedules and combination partners have been
designed for irinotecan. For second-line treatment, irino-
tecan has been tried as monotherapy—weekly or
biweekly—as well as in combination with 5-FU, capecit-
abine, cisplatin, or mitomycin [8–10, 18, 19]. These studies
demonstrated ORR of 15–30% and OS of 5–8 months.
However, IRIS has been tried only on previously untreated
patients. Two Japanese trials adopted biweekly irinotecan,
but its dosage differed from each other. Uedo et al. tried
80 mg/m2 (40 mg/m2/week) and reported ORR of 48%,
while Komatsu et al., derived from phase I study by
themselves, adopted 125 mg/m2 (62.5 mg/m2/week) to
obtain better ORR of 54% [20, 21]. A Korean study
favored triweekly schedule with 150 mg/m2 (50 mg/m2/
week) irinotecan with ORR of 49% [22]. Despite some
various ranges of S-1 dose among the studies, we thought
that these findings mainly implied dose–response rela-
tionship of irinotecan might exist. On designing this study,
we knew about the phase I study that biweekly 150 mg/m2
irinotecan did not bring about dose-limiting toxicity [23].
Additionally, a recent phase III study (GC0301/TOP-002)
comparing IRIS with S-1 monotherapy failed to demon-
strate the superiority of the combination therapy [23]. We
assumed that this failure might be due to the low dose
intensity of irinotecan (32 mg/m2/week), which is only half
the currently accepted dose. Therefore, we thought that
150 mg/m2 irinotecan could be tolerable, even in previ-
ously treated population, if their general condition is
permissible.
One critical point considered in designing second-line
treatment is the homogeneity of study population.
Fig. 1 Kaplan–Meier curves
a progression-free survival,
b overall survival
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Studies of a number of tumor types, including gastric
cancer, have shown that the progression-free interval
after first-line treatment correlates with a benefit from
second-line treatment [1, 24]. Therefore, we think that
our study offers clinical insight into high-risk patients
that progressed during or within 3 months of prior
chemotherapy.
The other point is the study aim. We set up the primary
endpoint as median survival, not the more traditional
endpoints, response rate. Although the activity of salvage
chemotherapy can be seen in terms of response rate, there
are substantial variations in findings (4–38%), which result
from small patient numbers and heterogenous populations
in terms of various different previous regimens [1].
Therefore, the interpretation of trials testing second-line
treatment by ORR is difficult. Moreover, in gastric cancer,
tumor response poorly correlates with survival and a study
demonstrates that the response of a primary gastric mass
poorly correlates with a metastatic lesion [25]. Patients
often progresses in non-measurable disease, most of which
cannot be measured by conventional imaging [26].
Therefore, we assumed that OS rather reflects the benefit
from chemotherapy especially in salvage setting, and the
more important is selecting subgroup most likely to benefit
from the chemotherapy. Of course, we admit that OS is not
an optimal endpoint, either; it is influenced by many other
factors including subsequent therapies; about half of
patients received subsequent therapy after the current
treatment. Other endpoints such as better symptom control,
quality of life, or improvement of performance might be
further investigated.
A pooled analysis of three randomized trials of fluoro-
uracil-based chemotherapy in AGC reported that the MST
of second-line chemotherapy was 5.6 months [27]. The
survival duration from PD to death after first-line treatment
in a recent Korean study reached 6.6 months, longer than
3–5 months in Western studies in which second-line or
subsequent salvage chemotherapies were not usually
offered [2]. Our study included heavily treated patients of
third- or fourth-line treatment, and we assumed that the
historical control of 3.8 months to be a reasonable refer-
ence. We designed to show a 75% increase in OS to
6.6 months, which we thought was somewhat high con-
sidering prior exposure to chemotherapy. Nevertheless, we
believe that this survival parameter is currently the mini-
mum range for the acceptance of irinotecan-containing
regimens aiming at salvage treatment in AGC [2, 8–10,
19]. We demonstrated that the MST reached 8.7 months.
Although direct comparison with previous phase II studies
is not amenable, our documented survival profiles are in
the upper level of other irinotecan-based combinations
[18, 28]. This could be partly explained that the patients
enrolled seem to be highly selected; they appeared to have
chemosensitive tumor on considering their previous che-
motherapy history and dose intensity and to have low
tumor burden (peritoneal metastasis 25%, liver metastasis
12%) when compared with previous studies of salvage
chemotherapy [18, 28]. Another factor could be a high
proportion of good performance status patients, and general
condition was maintained throughout the treatment course,
which enabled many patients to transfer to subsequent
chemotherapy protocols.
Table 4 Toxicity profile
Number of patients (%) Toxicity of
all grades (%)
Toxicity of
grades 3–4 (%)
Grade 1 Grade 2 Grade 3 Grade 4
Hematologic toxicity
Neutropenia 1 (3) 8 (21) 8 (21) 2 (5) 50 26
Anemia – 21 (55) 6 (16) 1 (3) 74 19
Leukopenia 9 (24) 6 (16) 9 (24) 1 (3) 67 27
Thrombocytopenia – 1 (3) – 1 (3) 6 3
Non-hematologic toxicity
Nausea/vomiting 4 (10) 12 (32) 1 (3) – 46 3
Mucositis 1 (3) 1 (3) 3 (8) – 8 8
Diarrhea 10 (26) 15 (39) 5 (13) 2 (5) 83 18
Hand–food syndrome 1 (3) 1 (3) 1 (3) – 9 3
Constipation 2 (5) 2 (5) – – 10 –
Peripheral neuropathy 1 (3) 3 (8) – – 11 –
Elevated creatinine 3 (8) – – – 8 –
Elevated liver enzyme 6 (16) 2 (5) 1 (3) – 24 3
Hyperbilirubinemia 3 (8) 1 (3) 1 (3) 1 (3) 19 6
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Because deteriorating performance status and nutri-
tional status are common in gastric cancer patients, to
select proper candidates who may benefit from salvage
treatment is important. We allowed previous exposure to
capecitabine, but none of these patients responded. The
group previously exposed to capecitabine had a signifi-
cantly shorter OS than capecitabine-naı¨ve group (relative
risk = 3.1, P = 0.012). In breast cancer, S-1 had very
limited activity in capecitabine-pretreated patients who
had already been exposed to anthracycline and taxanes,
which implies that S-1 clinically exhibited cross-resis-
tance to capecitabine [29]. Our data provide additional
evidence—although indirect—that capecitabine resistance
may adversely influence S-1 efficacy and should be a
consideration for eligibility in future clinical trials.
Another independent prognostic factor is hypoalbumine-
mia. Performance status was not a significant factor for
survival due to the small patient number of ECOG 2.
Instead, serum albumin level as a predictive marker
indicated that patients of hypoalbuminemia (B3.5 g/dL)
had 2.5 times higher risk of death. Hypoalbuminemia is
a consistent prognostic factor in gastric cancer patients in
palliative setting [30, 31]. Although many confounding
factors—comorbidity, anorexia/malnutrition, dysregula-
tion of cytokines, inflammation—associate between
albumin and survival, we suggest that serum albumin
could be used in clinical trials to better define the
baseline risk in AGC. We believe that visceral protein
depletion, inflammatory response markers, and nutritional
strategy should be further studied along with cancer-
specific therapy.
The incidence of neutropenia and diarrhea seemed
higher compared with other phase II studies of S-1 plus
irinotecan, which is comparable with capecitabine plus
irinotecan chemotherapy [19, 21–23]. The high-dose
intensity of irinotecan may, at least partly, contribute the
relative increase in toxicity. However, the development of
pharmacogenetic markers of irinotecan and S-1 can help us
determine, which patients might avoid excessive toxicity
while benefit from second-line chemotherapy.
To summarize, our first phase II study demonstrated
that biweekly IRIS regimen was well tolerated and
showed encouraging survival profile. These findings
reaffirm that irinotecan-based therapy has use as salvage
treatment for advanced gastric cancer. However, given
the high incidence of neutropenia and gastrointestinal
toxicity, proper patient selection may be warranted; rel-
atively younger patients (\65) with normal serum albu-
min level may the best candidates for the treatment,
while patients with liver metastasis compromising liver
functions or who have prior capecitabine exposure
should be an exclusion criteria for the application of this
regimen.
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